Assessment
Questionnaire
See what questions
a doctor would ask.
Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.
Source: Diseases Database
Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.
Source: MeSH 2007
These medical condition or symptom topics may be relevant to medical information for Selegiline:
Because many drug names share similar spellings or sound almost identical when spoken, it is possible to mistake the name of a particular medication. Other drugs that are sometimes confused with Selegiline include:
Source: Diseases Database
Source - MeSH 2007
Source - MeSH 2007
Source: CRISP
The following list attempts to classify Selegiline into categories where each line is subset of the next.
Source: Diseases Database
Search to find out more about Selegiline:
|
Tools & Services:
Medical Articles:
Search Specialists by State and City
By using this site you agree to our Terms of Use. Information provided on this site is for informational purposes only; it is not intended as a substitute for advice from your own medical team. The information on this site is not to be used for diagnosing or treating any health concerns you may have - please contact your physician or health care professional for all your medical needs. Please see our Terms of Use.
Copyright © 2011 Health Grades Inc. All rights reserved. Last Update: 7 May, 2013 (0:36)